MedCap AB (publ)

Research MedCap AB (publ) (MCAP) on Bullrun: valuation model: 8.6% overvalued, market cap SEK 8.48B, P/E 35.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks MedCap AB (publ) as 8.6% overvalued; latest market cap is SEK 8.48B; P/E is 35.3.

Peer valuation comparison

Latest P/E is 35.26x versus a Healthcare sector median of 24.46x (44.2% above).

Latest P/E is 35.26x versus a Sweden median of 18.57x (89.9% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 2.12BSEK 219.90Mn/a58.6%n/aSEK 370.40MSEK 482.90MSEK 1.45B
FY2024SEK 1.83BSEK 207.30Mn/a58.6%n/aSEK 370.10MSEK 358.00MSEK 1.28B
FY2023SEK 1.61BSEK 172.10Mn/a58.4%n/aSEK 188.20Mn/an/a
FY2022SEK 1.15BSEK 117.50Mn/a61.3%n/aSEK 236.20Mn/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23SEK 8.48B35.3n/an/a

About MedCap AB (publ)

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products;

Related stock research

Other Healthcare stocks

Frequently asked questions

Is MedCap AB (publ) overvalued or undervalued?

Bullrun's valuation model currently marks MedCap AB (publ) as 8.6% overvalued.

What is MedCap AB (publ)'s market cap?

MedCap AB (publ)'s market capitalization is SEK 8.48B.

What is MedCap AB (publ)'s P/E ratio?

MedCap AB (publ)'s price-to-earnings (P/E) ratio is 35.3.

What does MedCap AB (publ) do?

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; and Assistive Tech including digital and physical solutions in cognition, communication, environmental control, alarms, mobility, accessibility, and orthotics.